Conference Coverage

Intensified rifampicin boosts outcomes in TB/HIV coinfection

Publish date: August 13, 2016

 

AT AIDS 2016

References

The trial was funded by the European and Developing Countries Clinical Trials Partnership. Dr. Merle reported having no financial conflicts of interest.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Extended-release naltrexone helps alcohol-dependent HIV-positive prisoners transition to community
MDedge Family Medicine
New HIV antiretroviral guidelines embrace PrEP, early ART
MDedge Family Medicine
HIV research update: Late July 2016
MDedge Family Medicine
HIV chemoprophylaxis in U.S. up 738% in recent 3-year period
MDedge Family Medicine
HIV chemoprophylaxis shown effective in 15-year-olds
MDedge Family Medicine
Changes in HIV-related cancers reflect changes in HIV patient care
MDedge Family Medicine
CMV viremia not culprit in high mortality of TB/HIV coinfection
MDedge Family Medicine
Don’t delay treatment for patients with TB and HIV
MDedge Family Medicine
Monitoring renal function during daily oral HIV PrEP
MDedge Family Medicine
HIV-related lymphoma rate remains sky-high despite ART
MDedge Family Medicine